Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Common blood flow drug tested as potential new weapon against rheumatoid arthritis

NCT ID NCT05671497

Summary

This study tested whether adding the medication cilostazol to standard rheumatoid arthritis (RA) treatments could help patients feel better. For 6 months, 70 adults with moderate-to-severe RA either took their usual medications plus cilostazol or just their usual medications alone. Researchers checked if the added drug reduced joint pain, swelling, and internal inflammation more effectively.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Al-Zahraa Hospital

    Cairo, Egypt

Conditions

Explore the condition pages connected to this study.